Clozapine Administration in Adolescence Prevents Postpubertal Emergence of Brain Structural Pathology in an Animal Model of Schizophrenia

Biological Psychiatry

Volumn 66, Issue 11, 2009, Pages 1038-1046

  Piontkewitz, Yael ^a   Assaf, Yaniv ^a   Weiner, Ina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal model; clozapine; prenatal PolyI:C; prevention; schizophrenia; structural brain pathology

Indexed keywords

AMPHETAMINE; CLOZAPINE; POLYINOSINIC POLYCYTIDYLIC ACID; SODIUM CHLORIDE;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; DRUG EFFICACY; GESTATIONAL AGE; HIPPOCAMPUS; IMAGING; MALE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; PROGENY; RAT; SCHIZOPHRENIA;

ABNORMALITIES, DRUG-INDUCED; AGE FACTORS; AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; BRAIN DISEASES; CEREBRAL VENTRICLES; CLOZAPINE; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INHIBITION (PSYCHOLOGY); MALE; MOTOR ACTIVITY; POLY I-C; RATS; RATS, WISTAR; SCHIZOPHRENIA;

EID: 70350721661     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.07.005     Document Type: Article

References (66)

1. Mittal V.A., Ellman L.M., and Cannon T.D. Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. Schizophr Bull 34 (2008) 1083-1094
2. DeLisi L.E. The concept of progressive brain change in schizophrenia: Implications for understanding schizophrenia. Schizophr Bull 34 (2008) 312-321
3. Lawrie S.M., McIntosh A.M., Hall J., Owens D.G., and Johnstone E.C. Brain structure and function changes during the development of schizophrenia: The evidence from studies of subjects at increased genetic risk. Schizophr Bull 34 (2008) 330-340
4. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31 (2005) 672-696
5. Job D.E., Whalley H.C., Johnstone E.C., and Lawrie S.M. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage 25 (2005) 1023-1030
6. Waddington J.L. Neuroimaging and other neurobiological indices in schizophrenia: Relationship to measurement of functional outcome. Br J Psychiatry Suppl 50 (2007) s52-s57
7. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163 (2006) 790-799
8. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59 (2002) 921-928
9. McGorry P.D., Killackey E., and Yung A. Early intervention in psychosis: Concepts, evidence and future directions. World Psychiatry 7 (2008) 148-156
10. Ruhrmann S., Schultze-Lutter F., Maier W., and Klosterkotter J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry 20 (2005) 1-6
11. Lee C., McGlashan T.H., and Woods S.W. Prevention of schizophrenia: Can it be achieved?. CNS Drugs 19 (2005) 193-206
12. Salokangas R.K., and McGlashan T.H. Early detection and intervention of psychosis. A review. Nord J Psychiatry 62 (2008) 92-105
13. Lieberman J.A., and Fenton W.S. Delayed detection of psychosis: Causes, consequences, and effect on public health. Am J Psychiatry 157 (2000) 1727-1730
14. Rosen A. Ethics of early prevention in schizophrenia. Aust N Z J Psychiatry 34 (2000) S208-S212
15. Marshall M., and Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev (2006) CD004718
16. Corcoran C., Malaspina D., and Hercher L. Prodromal interventions for schizophrenia vulnerability: The risks of being "at risk". Schizophr Res 73 (2005) 173-184
17. McGlashan T.H., Addington J., Cannon T., Heinimaa M., McGorry P., O'Brien M., et al. Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull 33 (2007) 715-726
18. Richtand N.M., Taylor B., Welge J.A., Ahlbrand R., Ostrander M.M., Burr J., et al. Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 31 (2006) 77-89
19. Steen R.G., Mull C., McClure R., Hamer R.M., and Lieberman J.A. Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 188 (2006) 510-518
20. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., and Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: A longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 60 (2003) 585-594
21. Meyer U., Spoerri E., Yee B.K., Schwarz M.J., and Feldon J. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. [published online ahead of print October 8]. Schizophr Bull (2008) doi:10.1093/schbul/sbn131
22. Meyer U., Feldon J., Schedlowski M., and Yee B.K. Towards an immunoprecipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29 (2005) 913-947
23. Shi L., Fatemi S.H., Sidwell R.W., and Patterson P.H. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23 (2003) 297-302
24. Zuckerman L., Rehavi M., Nachman R., and Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28 (2003) 1778-1789
25. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 32 (2006) 200-202
26. Patterson P.H. Neuroscience. Maternal effects on schizophrenia risk. Science 318 (2007) 576-577
27. Meyer U., Yee B.K., and Feldon J. The neurodevelopmental impact of prenatal infections at different times of pregnancy: The earlier the worse?. Neuroscientist 13 (2007) 241-256
28. Ozawa K., Hashimoto K., Kishimoto T., Shimizu E., Ishikura H., and Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59 (2006) 546-554
29. Zuckerman L., and Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39 (2005) 311-323
30. Zuckerman L., and Weiner I. Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation. Psychopharmacology 169 (2003) 308-313
31. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24 (2000) 417-463
32. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
33. Romero E., Ali C., Molina-Holgado E., Castellano B., Guaza C., and Borrell J. Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology 32 (2007) 1791-1804
34. Suzuki M., Hagino H., Nohara S., Zhou S.Y., Kawasaki Y., Takahashi T., et al. Male-specific volume expansion of the human hippocampus during adolescence. Cereb Cortex 15 (2005) 187-193
35. Giedd J.N., Vaituzis A.C., Hamburger S.D., Lange N., Rajapakse J.C., Kaysen D., et al. Quantitative MRI of the temporal lobe, amygdala, and hippocampus in normal human development: Ages 4-18 years. J Comp Neurol 366 (1996) 223-230
36. Benes F.M., Turtle M., Khan Y., and Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry 51 (1994) 477-484
37. Bayer S.A., Yackel J.W., and Puri P.S. Neurons in the rat dentate gyrus granular layer substantially increase during juvenile and adult life. Science 216 (1982) 890-892
38. Newton S.S., and Duman R.S. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21 (2007) 715-725
39. Makinodan M., Tatsumi K., Manabe T., Yamauchi T., Makinodan E., Matsuyoshi H., et al. Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res 86 (2008) 2190-2200
40. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 26 (2006) 4752-4762
41. Nieman B.J., Bishop J., Dazai J., Bock N.A., Lerch J.P., Feintuch A., et al. MR technology for biological studies in mice. NMR Biomed 20 (2007) 291-303
42. Torres G., Meeder B.A., Hallas B.H., Spernyak J.A., Mazurchuk R., Jones C., et al. Ventricular size mapping in a transgenic model of schizophrenia. Brain Res Dev Brain Res 154 (2005) 35-44
43. Lodygensky G.A., Inder T.E., and Neil J.J. Application of magnetic resonance imaging in animal models of perinatal hypoxic-ischemic cerebral injury. Int J Dev Neurosci 26 (2008) 13-25
44. Pantelis C., Wood S.J., Yücel M., Phillips L.J., Yung A., Garner B., et al. Structural brain changes are progressive at the earliest stages of psychosis. Evidence from the Melbourne longitudinal studies. Schizophr Res 102 (2008) S35
45. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63 (2006) 139-149
46. Jarskog L.F., Miyamoto S., and Lieberman J.A. Schizophrenia: New pathological insights and therapies. Annu Rev Med 58 (2007) 49-61
47. Vita A., and De Peri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int Rev Psychiatry 19 (2007) 429-436
48. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62 (2005) 361-370
49. Ben-Ari Y. Neuro-archaeology: Pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci 31 (2008) 626-636
50. Wood G.K., Lipska B.K., and Weinberger D.R. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Res Dev Brain Res 101 (1997) 17-25
51. Zuckerman L., Rimmerman N., and Weiner I. Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: Implications for neurodevelopmental models of schizophrenia. Psychopharmacology 169 (2003) 298-307
52. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18 (1977) 137-165
53. Laviola G., Adriani W., Terranova M.L., and Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 23 (1999) 993-1010
54. Moran-Gates T., Gan L., Park Y.S., Zhang K., Baldessarini R.J., and Tarazi F.I. Repeated antipsychotic drug exposure in developing rats: Dopamine receptor effects. Synapse 59 (2006) 92-100
55. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50 (2001) 884-897
56. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71 (2003) 127-131
57. Wakade C.G., Mahadik S.P., Waller J.L., and Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 69 (2002) 72-79
58. Guillin O., Abi-Dargham A., and Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78 (2007) 1-39
59. Andersen S.L., Thompson A.T., Rutstein M., Hostetter J.C., and Teicher M.H. Dopamine receptor pruning in prefrontal cortex during the prereadolescent period in rats. Synapse 37 (2000) 167-169
60. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533
61. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93 (1996) 9235-9240
62. Hajos M. Targeting information-processing deficit in schizophrenia: A novel approach to psychotherapeutic drug discovery. Trends Pharmacol Sci 27 (2006) 391-398
63. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160 (2003) 13-23
64. Weiner I. The "two-headed" latent inhibition model of schizophrenia: Modeling positive and negative symptoms and their treatment. Psychopharmacology 169 (2003) 257-297
65. Prasad K.M., and Keshavan M.S. Structural cerebral variations as useful endophenotypes in schizophrenia: Do they help construct "extended endophenotypes"?. Schizophr Bull 34 (2008) 774-790
66. Wolf O.T., Dyakin V., Vadasz C., de Leon M.J., McEwen B.S., and Bulloch K. Volumetric measurement of the hippocampus, the anterior cingulate cortex, and the retrosplenial granular cortex of the rat using structural MRI. Brain Res Brain Res Protoc 10 (2002) 41-46